Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03279692 · ClinicalTrials.gov registry record · Phase 2
Phase II Trial of Pembrolizumab in Recurrent or Residual High Grade Meningioma
A Phase 2 study of High Grade Meningioma, sponsored by Massachusetts General Hospital.
- Active
- Registry status
- Phase 2
- Development phase
- 26
- Enrollment target
- 2
- Study locations
NCT03279692 is a Phase 2 study of High Grade Meningioma that is active but no longer recruiting, run by Massachusetts General Hospital. The registered enrollment target is 26 participants. The trial reports 2 study locations across 1 state.
The verdict
NCT03279692, a Phase 2 study of High Grade Meningioma, is active but no longer recruiting, sponsored by Massachusetts General Hospital.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 26 participants
- Enrollment target
- 2
- Study locations
Study Summary
This research study is studying a drug as a possible treatment for High Grade Meningioma. The drug involved in this study is an immunotherapy drug called pembrolizumab
Conditions Studied
Interventions
- DRUG Pembrolizumab
Study Locations (2)
Massachusetts
- Dana Farber Cancer Institute - Boston
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2017-11-07 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03279692
The ClinicalTrials.gov registry entry for NCT03279692 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with High Grade Meningioma appearing as the primary indexed condition, and to 1 intervention - of which Pembrolizumab is the first listed.
NCT03279692 reports 2 study locations spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT03279692 about?
NCT03279692 is a clinical study titled "Phase II Trial of Pembrolizumab in Recurrent or Residual High Grade Meningioma". This research study is studying a drug as a possible treatment for High Grade Meningioma. The drug involved in this study is an immunotherapy drug called pembrolizumab
What is the current status of trial NCT03279692?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 26 participants. The study started on 2017-11-07. Estimated completion is 2026-12-31.
What conditions does trial NCT03279692 study?
This clinical trial studies the following conditions: High Grade Meningioma.
What interventions are being tested in trial NCT03279692?
The interventions under investigation include: Pembrolizumab (DRUG).
Who is sponsoring clinical trial NCT03279692?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03279692 being conducted?
This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.